{"id":1300,"date":"2026-11-12T12:52:04","date_gmt":"2026-11-12T10:52:04","guid":{"rendered":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/"},"modified":"2026-11-12T12:52:11","modified_gmt":"2026-11-12T10:52:11","slug":"the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/","title":{"rendered":"The European Health Data Space: What Regulation (EU) 2025\/327 Means for Pharmaceutical Companies"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>The European Health Data Space Regulation, Regulation (EU) 2025\/327, entered into force on 26 March 2025. Its obligations apply in stages from 2027 to 2035, and they will change how health data can be reused for research, regulatory evidence and health technology assessment. For pharmaceutical companies the EHDS is both an opportunity and a set of new obligations, and the preparation window is already open.<\/strong><\/p>\n\n<h2>Two pillars: primary and secondary use<\/h2>\n<p>The EHDS has two strands. <strong>Primary use<\/strong> gives patients electronic access to their own health data and lets health professionals exchange it across borders, starting with patient summaries and ePrescriptions. <strong>Secondary use<\/strong> creates a regulated route for reusing electronic health data for research, innovation, policy-making, regulatory activities and personalised medicine. Access is granted through national <strong>health data access bodies<\/strong>, which issue data permits for analysis in secure processing environments.<\/p>\n\n<h2>The timeline that matters<\/h2>\n<ul>\n<li><strong>26 March 2025<\/strong>: entry into force.<\/li>\n<li><strong>26 March 2027<\/strong>: general date of application. Implementing rules on templates for data access applications, secure processing environments and dataset descriptions begin to apply.<\/li>\n<li><strong>26 March 2029<\/strong>: exchange of the first priority data categories, and most of the secondary-use framework applies.<\/li>\n<li><strong>26 March 2031<\/strong>: second-wave categories such as medical images, laboratory results and discharge reports, plus further secondary-use categories including genomic data.<\/li>\n<li><strong>26 March 2035<\/strong>: third countries and international organisations can apply to join the HealthData@EU infrastructure.<\/li>\n<\/ul>\n\n<h2>Opportunities for industry<\/h2>\n<p>Once access bodies are running, companies will be able to apply for permits to analyse anonymised or pseudonymised data across Member States. The data could be used for:<\/p>\n<ul>\n<li>real-world evidence to support regulatory submissions and post-authorisation studies<\/li>\n<li>evidence on unmet need, treatment patterns and outcomes for HTA and pricing negotiations<\/li>\n<li>pharmacovigilance and drug utilisation research.<\/li>\n<\/ul>\n<p>For Greece, where routine data sources such as e-prescription records are already well developed, the EHDS could make national data more visible and more usable within European evidence-generation projects.<\/p>\n\n<h2>Obligations for data holders<\/h2>\n<p>Companies may also be <strong>data holders<\/strong>, for example of clinical trial or registry data. The Regulation contains safeguards for intellectual property and trade secrets, but the practical boundaries will be set by implementing acts, guidance and how national access bodies apply them. Companies should:<\/p>\n<ul>\n<li>map which of their datasets could fall within the secondary-use categories<\/li>\n<li>review consent language, data-sharing agreements and the interface with the GDPR and the Clinical Trials Regulation<\/li>\n<li>decide how they will identify and justify protection of commercially confidential information.<\/li>\n<\/ul>\n\n<h2>How PQRA helps<\/h2>\n<p>PQRA helps pharmaceutical companies turn new data frameworks into practical evidence strategies. We assess EHDS readiness, connect real-world data planning with regulatory and HTA needs, and support data-holder obligations alongside your legal and data-protection teams.<\/p>\n<p><a href=\"\/el\/contact\/\">Discuss your EHDS readiness with PQRA &rarr;<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The European Health Data Space Regulation, Regulation (EU) 2025\/327, entered into force on 26 March 2025. Its obligations apply in stages from 2027 to 2035, and they will change how health data can be reused for research, regulatory evidence and health technology assessment. For pharmaceutical companies the EHDS is both an opportunity and a set [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1301,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The European Health Data Space: What Regulation (EU) 2025\/327 Means for Pharmaceutical Companies - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The European Health Data Space: What Regulation (EU) 2025\/327 Means for Pharmaceutical Companies - PQRA\" \/>\n<meta property=\"og:description\" content=\"The European Health Data Space Regulation, Regulation (EU) 2025\/327, entered into force on 26 March 2025. Its obligations apply in stages from 2027 to 2035, and they will change how health data can be reused for research, regulatory evidence and health technology assessment. For pharmaceutical companies the EHDS is both an opportunity and a set [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T10:52:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-12T10:52:11+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"The European Health Data Space: What Regulation (EU) 2025\\\/327 Means for Pharmaceutical Companies\",\"datePublished\":\"2026-11-12T10:52:04+00:00\",\"dateModified\":\"2026-11-12T10:52:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ehds-pharma.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/\",\"name\":\"The European Health Data Space: What Regulation (EU) 2025\\\/327 Means for Pharmaceutical Companies - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ehds-pharma.png\",\"datePublished\":\"2026-11-12T10:52:04+00:00\",\"dateModified\":\"2026-11-12T10:52:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ehds-pharma.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ehds-pharma.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The European Health Data Space: What Regulation (EU) 2025\\\/327 Means for Pharmaceutical Companies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The European Health Data Space: What Regulation (EU) 2025\/327 Means for Pharmaceutical Companies - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/","og_locale":"el_GR","og_type":"article","og_title":"The European Health Data Space: What Regulation (EU) 2025\/327 Means for Pharmaceutical Companies - PQRA","og_description":"The European Health Data Space Regulation, Regulation (EU) 2025\/327, entered into force on 26 March 2025. Its obligations apply in stages from 2027 to 2035, and they will change how health data can be reused for research, regulatory evidence and health technology assessment. For pharmaceutical companies the EHDS is both an opportunity and a set [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/","og_site_name":"PQRA","article_published_time":"2026-11-12T10:52:04+00:00","article_modified_time":"2026-11-12T10:52:11+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"2 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"The European Health Data Space: What Regulation (EU) 2025\/327 Means for Pharmaceutical Companies","datePublished":"2026-11-12T10:52:04+00:00","dateModified":"2026-11-12T10:52:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ehds-pharma.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/","url":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/","name":"The European Health Data Space: What Regulation (EU) 2025\/327 Means for Pharmaceutical Companies - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ehds-pharma.png","datePublished":"2026-11-12T10:52:04+00:00","dateModified":"2026-11-12T10:52:11+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ehds-pharma.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ehds-pharma.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/the-european-health-data-space-what-regulation-eu-2025-327-means-for-pharmaceutical-companies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"The European Health Data Space: What Regulation (EU) 2025\/327 Means for Pharmaceutical Companies"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1300"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1300\/revisions"}],"predecessor-version":[{"id":1302,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1300\/revisions\/1302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1301"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}